Vision Medicals is a gene technology and precision medicine company.
Vision Medicals is a provider of pathogenic gene diagnostic services, focusing on infection-precise medical treatment, high-throughput sequencing-based pathogen metagenomics and CRISPR-based rapid diagnosis and other new technologies, effectively improving the detection ability of clinical pathogens and shortening The reporting cycle accelerated the development of the infection-accurate medical industry. The company developed a pathogenic nucleic acid enrichment technology with independent intellectual property rights for the detection of pathogenic micronucleic acids in clinical samples. The pathogen macro was established through the accumulation of pathogen detection big data. Genomics intelligent analysis and reporting system.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Aug 12, 2020 | Series B | ¥200M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
CICC Qichen | — | Series B |